Dextra Laboratories Overview

  • Year Founded
  • 1989

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 26

Employees

  • Latest Deal Type
  • Grant

  • Financing Rounds
  • 3

Dextra Laboratories General Information

Description

Provider of biological research intended for the total synthesis of challenging complex carbohydrates. The company offers carbohydrate research, synthesis and analysis, discovery chemistry, route scouting, process development, tox batches, carbohydrate building blocks and combinatorial libraries, thereby enabling its clients to minimize costs, reduce technology transfer issues and optimize robust route generation.

Contact Information

Website
www.dextrauk.com
Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Private Equity-Backed
Primary Industry
Laboratory Services (Healthcare)
Other Industries
Other Pharmaceuticals and Biotechnology
Parent Company
New Zealand Pharmaceuticals
Primary Office
  • Thames Valley Science Park
  • The Gateway, 1 Collegiate Square
  • Reading RG2 9LH
  • England, United Kingdom
+44 0118 000 0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Dextra Laboratories Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Dextra Laboratories‘s full profile, request access.

Request a free trial

Dextra Laboratories Patents

  • 43

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 000

    Granted

  • 000

    Pending

  • 000

    Expiring in next 12 mo

Dextra Laboratories Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
GB-201610862-D0 Compounds Inactive 22-Jun-2016
GB-201609104-D0 Compounds Inactive 24-May-2016
GB-201608778-D0 Compounds Inactive 18-May-2016
GB-201515185-D0 Glycosylation process Inactive 26-Aug-2015
GB-201510760-D0 Compounds Inactive 18-Jun-2015
To view Dextra Laboratories’s complete patent history, request access »

Dextra Laboratories Executive Team (5)

Name Title Board Seat Contact Info
Alex Weymouth-Wilson Ph.D Chief Scientific Officer
Agostino Barazza Chief Executive Officer
You’re viewing 2 of 5 executive team members. Get the full list »

Dextra Laboratories Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Dextra Laboratories Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Dextra Laboratories‘s full profile, request access.

Request a free trial